Poor
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment is poor. The claims largely omit or contradict key label provisions (contraindications, boxed warnings, pregnancy/pediatric safety, retinopathy/AKI risks), and several asserted statements are not supported by the labeling. A few statements about initiation dosing and GI adverse effects align, but many safety and regulatory aspects are not adequately represented.
Category Scores
Accurate Statements
Ozempic (semaglutide) is used for type 2 diabetes.
Indications and Usage: 1
Ozempic causes mostly gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation.
Adverse Reactions: 6.1
The typical Ozempic initiation dosing is 0.25 mg weekly for 4 weeks.
Dosing and Administration: 2.2
Monitor with doctor; report if lasting >4 weeks.
Patient Counseling Information: 17
Unsupported Statements
Ozempic (semaglutide) is used for weight management.
Label does not support Ozempic weight management; Wegovy labeling is for weight management.
Side effects start within the first week of treatment due to dose escalation.
Label indicates GI adverse reactions occur during dose escalation but does not specify start within the first week.
After 4 weeks, the dose is increased to 0.5 mg weekly, up to 2.4 mg weekly for weight loss under Wegovy branding.
Label supports escalation to 0.5 mg and up to 2 mg for Ozempic; 2.4 mg and Wegovy branding pertain to obesity labeling outside Ozempic’s indications.
Most common side effects peak in the first 4-8 weeks and resolve or significantly improve within 1-3 months for 70-80% of patients, especially with gradual dosing.
Not described in the label.
Nausea affects up to 44% initially but drops to under 10% after 26 weeks in clinical trials.
Label data show different percentages (e.g., 6.1%–20% range in cited tables); 44% is not supported.
In the SUSTAIN trials, nausea incidence fell from 20% in week 1 to 5% by week 52.
Not described in the Ozempic labeling; SUSTAIN trials are not indicated in the label excerpt provided.
Diarrhea and vomiting fade as gut motility adapts to GLP-1 receptor agonism.
Not explicitly stated in the label excerpt.
Persistent issues beyond 3 months occur in under 5% of users and may require dose reduction or anti-nausea meds like ondansetron.
Not explicitly stated in the label excerpt.
For the minority (10-20%), symptoms like severe nausea or gastroparesis-like effects can last 6+ months or until discontinuation.
Not explicitly stated in the label excerpt.
Rare cases report lingering gallbladder issues or pancreatitis signals post-stopping, though causality is debated.
Postmarketing/causal discussion is broader; not explicitly framed this way in label excerpt.
FDA labels note 1-2% discontinuation rate due to GI intolerance.
Label data show 3.1%–3.8% discontinuation due to GI adverse reactions in the cited table; 1-2% is not supported.
Higher starting doses or rapid escalation prolongs issues.
Label supports cautious escalation to reduce GI AEs; claim is partially aligned but requires precise dose-escalation context.
Women, older adults, and those with prior GI conditions experience longer effects.
Not described in the label excerpt provided.
Alcohol or fatty meals worsen acute symptoms.
Not described in the label excerpt.
Stopping Ozempic resolves most within 4-6 weeks due to 1-week half-life, but weight regain follows.
Pharmacokinetics state ~1-week half-life and ~5 weeks presence post-dose; weight regain is not a label statement.
Beyond GI, watch for thyroid tumors (black box warning, rodent data), vision changes, or kidney effects—rare (<1%) and not always reversible.
Partially supported; boxed warning exists for thyroid C-cell tumors and retinopathy/kidney risks are described; specific prevalence (<1%) is not stated.
No confirmed link to permanent damage in humans.
Not stated in the label excerpt; requires caution.
Lawsuits claim prolonged gastroparesis; causality debated.
Postmarketing/legal claims; not a labeling statement.
Contradictions
Low
AI Statement
Nausea affects up to 44% initially but drops to under 10% after 26 weeks in clinical trials.
Label Reference
Adverse Reactions: 6.1
Low
AI Statement
FDA labels note 1-2% discontinuation rate due to GI intolerance.
Label Reference
Adverse Reactions: 6.1
Important Omissions
Explicit contraindications (personal or family history of MTC, MEN2; hypersensitivity) are not stated in the findings.
Importance:
High
Boxed warning clearly articulating risk of thyroid C-cell tumors and human relevance.
Importance:
High
Pregnancy safety data and guidance (8.1, 8.3) explicitly referenced; pediatric safety data (8.4) not cited in assignments.
Importance:
High
Pediatric safety (ages and conditions) details for safety in patients 10 years and older with type 2 diabetes.
Importance:
High
Renal and retinopathy risks associated with rapid glycemic control and dehydration-related AKI; monitoring considerations.
Importance:
High
Hypoglycemia risk with concomitant insulin secretagogues or insulin; monitoring guidance for combination therapy.
Importance:
High
Cholelithiasis and pancreatitis risk with ongoing monitoring guidance.
Importance:
High
Clarification to avoid conflating Ozempic with Wegovy weight-management labeling and dosing (Wegovy 2.4 mg weekly).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label-supported GI adverse events exist but with established risk mitigation (dose escalation to reduce GI AEs) and boxed warnings for thyroid tumors; remaining safety topics require explicit inclusion.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Need to align statements with label by clearly distinguishing Ozempic indications/dosing from Wegovy weight-management labeling, and by incorporating contraindications, boxed warning, pregnancy/pediatric safety, and explicit retinopathy/AKI considerations.
Suggested Improvement
Add explicit contraindications (MTC/MEN2; hypersensitivity); highlight boxed warning for thyroid C-cell tumors; include pregnancy and pediatric use details; address renal/retinopathy risks with rapid glycemic control; clarify hypoglycemia risk with combination therapy; separate weight-management claims to Wegovy labeling to avoid cross-product confusion; avoid unsupported numeric prevalence claims.